RxDoctor Payments DataLook up a doctor →

Shahid Malik, MD

Hematology & Oncology · Las Vegas, NVNPI 1588635312

Payments from drug & device makers

$13,760in general payments, 2019–2025

Across 650 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Amgen$884
  • Johnson & Johnson$802
  • Bayer$634
  • AstraZeneca$634
  • Merck$574
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis60$1,852
Amgen37$884
Johnson & Johnson(2 entities)40$802
Bayer35$634
AstraZeneca(2 entities)33$634
Merck31$574
E.r. Squibb & Sons, L.L.C.34$563
Incyte Corporation27$535
Sanofi24$464
Genentech USA, Inc.19$347
Seagen Inc.20$325
Astellas Pharma US Inc15$324
Boehringer Ingelheim12$307
Bristol Myers Squibb18$286
Regeneron Healthcare Solutions, Inc.8$277
Sobi, Inc10$270
Daiichi Sankyo Inc.15$268
Gilead(2 entities)16$253
GSK6$252
Eisai Inc.12$225
AVEO Pharmaceuticals, Inc.7$217
Sanofi-aventis U.S. LLC3$200
Rigel Pharmaceuticals, Inc.9$184
Pfizer10$184
Pharmaessentia USA Corporation8$179
EMD Serono, Inc.6$137
Myovant Sciences Inc.6$132
Alnylam Pharmaceuticals Inc.6$128
Array Biopharma Inc7$126
Beigene USA, Inc.5$121
Clovis Oncology, Inc.8$111
Genmab U.S., Inc.4$110
Takeda Pharmaceuticals U.S.A., Inc.5$110
Ipsen Biopharmaceuticals, Inc6$104
Lilly USA, LLC6$101
Exelixis Inc.5$101
Pharmacosmos Therapeutics Inc.5$96
Pharmacyclics LLC, An Abbvie Company5$95
Spectrum Pharmaceuticals Inc.5$94
Puma Biotechnology, Inc.5$89
AMAG Pharmaceuticals, Inc.5$83
Jazz Pharmaceuticals Inc.3$67
Aurobindo Pharma USA, Inc.2$62
Dova Pharmaceuticals5$61
Agios Pharmaceuticals, Inc.3$58
EUSA Pharma (US) LLC3$51
Tempus AI, Inc2$47
Tolmar, Inc.2$38
Lexicon Pharmaceuticals, Inc.2$34
Secura Bio, Inc.2$33
Morphosys, US Inc.2$32
Pharming Healthcare, Inc.1$32
Janssen Scientific Affairs, LLC1$29
Progenics Pharmaceuticals, Inc.1$28
Dendreon Pharmaceuticals LLC1$27
Taiho Oncology, Inc.2$27
Teva Pharmaceuticals USA, Inc.2$26
Amneal Pharmaceuticals LLC1$26
Novocure Inc.1$24
Coherus Oncology, Inc.1$24

How this compares

$13,760 in reported general payments places this provider in the 40th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024
$511,863
Medicare patients
359
Services billed
58,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →